Cell growth factor is solved or aging "password" is found
January 24, 2018 Source: Science and Technology Daily
Window._bd_share_config={ "common":{ "bdSnsKey":{ },"bdText":"","bdMini":"2","bdMiniList":false,"bdPic":"","bdStyle":" 0","bdSize":"16"},"share":{ }};with(document)0[(getElementsByTagName('head')[0]||body).appendChild(createElement('script')) .src='http://bdimg.share.baidu.com/static/api/js/share.js?v=89860593.js?cdnversion='+~(-new Date()/36e5)];Wenzhou Medical University - Professor of the Biomedical Collaborative Innovation Center of Wenzhou University, Professor Li Chauzhen, revealed in an interview with the Science and Technology Daily on the 23rd that his leading research team and the team of Professor Moosa Mohammadi of New York University Medical Center have been working together for several years. The first analysis of the growth factor FGF23 and other structures, found the aging "password." Relevant research results have been published in the international academic journal Nature.
Growth factors are proteins involved in the repair, regulation and regeneration of the human body. There is a 20-year speculation in the international medical community that the protein α-klotho is a factor that can independently exert aging regulation. However, the research team of Wenhua University found that the regulation of aging is attributed to fibroblast growth factor 23 (FGF23). The so-called regulation of aging function of α-klotho is achieved by complexing with FGF23 and FGFR1 and assisting the latter.
Li Xiaoyu said that some members of the growth factor FGF family can participate in metabolic regulation, treat wound ulcers, promote the regeneration of damaged tissues, and promote the repair of aging and scar skin.
Studies have shown that FGF23 is also a key therapeutic target for chronic kidney disease. The research of Wenjida University also provides a clear structural blueprint for the development of new kidney disease diagnostic reagents and therapeutic drugs. Li Xiaoyu said that their team is currently accelerating the development of new kidney disease diagnostic reagents and therapeutic drugs.
Li Xiaoyu led the team to explore and study the relationship between cell growth factors and human diseases for 25 years. It is the world's first development of the growth factor FGF as a new class of drugs. As of 2017, the three new drugs developed by the team have been used in China for 80 million trauma patients, providing important emergency treatment drugs for the Wenchuan earthquake and the Tianjin Tanggu explosion. The paper published this time is also the research result of the team undertaking the 863 program and the national key research and development project. (Reporter Li He)
Striped Bonito,Sarda orientalis,Fresh Striped Bonito,Fresh Sarda orientalis
Zhoushan Boda Aquatic Products Co.,Ltd , https://www.baida-aquatic.com